These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 22072486)
21. Effects of monensin liposomes on the cytotoxicity, apoptosis and expression of multidrug resistance genes in doxorubicin-resistant human breast tumour (MCF-7/dox) cell-line. Shaik MS; Chatterjee A; Singh M J Pharm Pharmacol; 2004 Jul; 56(7):899-907. PubMed ID: 15233869 [TBL] [Abstract][Full Text] [Related]
22. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR. Zhang Y; Qu XJ; Liu YP; Yang XH; Hou KZ; Teng YE; Zhang JD Ai Zheng; 2009 Feb; 28(2):97-9. PubMed ID: 19550116 [TBL] [Abstract][Full Text] [Related]
23. Cancer-associated fibroblasts promote non-small cell lung cancer cell invasion by upregulation of glucose-regulated protein 78 (GRP78) expression in an integrated bionic microfluidic device. Yu T; Guo Z; Fan H; Song J; Liu Y; Gao Z; Wang Q Oncotarget; 2016 May; 7(18):25593-603. PubMed ID: 27016417 [TBL] [Abstract][Full Text] [Related]
24. Enhanced expression of stem cell markers and drug resistance in sphere-forming non-small cell lung cancer cells. Sun FF; Hu YH; Xiong LP; Tu XY; Zhao JH; Chen SS; Song J; Ye XQ Int J Clin Exp Pathol; 2015; 8(6):6287-300. PubMed ID: 26261505 [TBL] [Abstract][Full Text] [Related]
25. Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells. Zhu FS; Chen XM; Huang ZG; Wang ZR; Zhang DW; Zhang X J Dig Dis; 2010 Feb; 11(1):34-42. PubMed ID: 20132429 [TBL] [Abstract][Full Text] [Related]
26. 3β-Acetyl tormentic acid reverts MRP1/ABCC1 mediated cancer resistance through modulation of intracellular levels of GSH and inhibition of GST activity. Rocha Gda G; Oliveira RR; Kaplan MA; Gattass CR Eur J Pharmacol; 2014 Oct; 741():140-9. PubMed ID: 25111243 [TBL] [Abstract][Full Text] [Related]
27. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells. Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169 [TBL] [Abstract][Full Text] [Related]
28. Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth. Jung SK; Lee MH; Lim DY; Lee SY; Jeong CH; Kim JE; Lim TG; Chen H; Bode AM; Lee HJ; Lee KW; Dong Z Mol Carcinog; 2015 Apr; 54(4):322-31. PubMed ID: 24974831 [TBL] [Abstract][Full Text] [Related]
29. Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system. Pakunlu RI; Wang Y; Tsao W; Pozharov V; Cook TJ; Minko T Cancer Res; 2004 Sep; 64(17):6214-24. PubMed ID: 15342407 [TBL] [Abstract][Full Text] [Related]
30. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342 [TBL] [Abstract][Full Text] [Related]
31. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines. Badinloo M; Esmaeili-Mahani S Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575 [TBL] [Abstract][Full Text] [Related]
32. Combination of arsenic trioxide and chemotherapy in small cell lung cancer. Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618 [TBL] [Abstract][Full Text] [Related]
33. Multidrug resistance protein 1 (ABCC1) confers resistance to arsenic compounds in human myeloid leukemic HL-60 cells. Xu S; Zhang YF; Carew MW; Hao WH; Loo JF; Naranmandura H; Le XC Arch Toxicol; 2013 Jun; 87(6):1013-23. PubMed ID: 23052202 [TBL] [Abstract][Full Text] [Related]
34. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway. Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778 [TBL] [Abstract][Full Text] [Related]
35. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Li J; Viallet J; Haura EB Cancer Chemother Pharmacol; 2008 Mar; 61(3):525-34. PubMed ID: 17505826 [TBL] [Abstract][Full Text] [Related]
36. [Human lung cancer: role of TLR7 and TLR8 in cell survival and chemoresistance]. Cherfils-Vicini J; Damotte D; Fridman WH; Sautès-Fridman C; Cremer I Med Sci (Paris); 2010 Apr; 26(4):435-7. PubMed ID: 20412752 [No Abstract] [Full Text] [Related]
37. Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Morrow CS; Peklak-Scott C; Bishwokarma B; Kute TE; Smitherman PK; Townsend AJ Mol Pharmacol; 2006 Apr; 69(4):1499-505. PubMed ID: 16434618 [TBL] [Abstract][Full Text] [Related]
38. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines. Jiang Y; Li C; Ma Y; Chen J; Li Y; Chen L Clin Lab; 2012; 58(5-6):551-61. PubMed ID: 22783588 [TBL] [Abstract][Full Text] [Related]
39. The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Abdul-Ghani R; Serra V; Györffy B; Jürchott K; Solf A; Dietel M; Schäfer R Oncogene; 2006 Mar; 25(12):1743-52. PubMed ID: 16288223 [TBL] [Abstract][Full Text] [Related]
40. Defects in apoptotic signal transduction in cisplatin-resistant non-small cell lung cancer cells. Ikuta K; Takemura K; Kihara M; Naito S; Lee E; Shimizu E; Yamauchi A Oncol Rep; 2005 Jun; 13(6):1229-34. PubMed ID: 15870947 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]